University of California, Los Angeles

LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announces a forthcoming panel discussion and poster presentation at the 7th Annual Los Angeles Bioscience Ecosystem Summit 2025 (“LABEST”). Panel Discussion Details: Title: BioSuccess in Los AngelesCEO Panelists: Ken Schultz (Trethera), Daniel Gil (Pelage), Dina Leeds (CleopatraRx), and Bethany Mancilla (Capsida)Moderator: Amir Naiberg, Associate Vice Chancellor, UCLA; CEO and President, UCLA Technology Development GroupLocation: Centennial Ballroom, 1st floor, Luskin Conference CenterDate: Thursday, May 22, 2025 at 2PM Poster Details: Title: First-in-Class Clinical Stage Deoxycytidine Kinase Inhibitor Blocks Inflammatory Bowel Disease Symptoms in an Adoptive CD4 T Cell Transfer Mouse ModelAuthors: Peter M. Clark, PhD; Kenneth A. Schultz, MD; KM Ryan, BSCategory: Immunity, Inflammation, Infection and Transplantation (I3T)Location: Pearl Cohen Scientific Poster Competition, Luskin Conference CenterDate: Thursday, May 22, 2025 at 4PM LABEST 2025 is the premier showcase for bioscience innovation in Los Angeles County and is produced by the UCLA Technology Development Group. The conference attracts over 1,500 life science industry professionals from the world’s leading pharmaceutical companies, venture capital firms, and research institutions. LABEST is intended to promote awareness of the growing life science entrepreneurial ecosystem in Los Angeles and to foster partnerships with the biotechnology and life science industry. Poster co-author Peter M. Clark is an Associate Professor of Molecular and Medical Pharmacology at the David Geffen School of Medicine and Crump Institute for Molecular Imaging at UCLA. Dr. Clark identified the metabolic enzyme deoxycytidine kinase, dCK, as a key and targetable enzyme required for aberrant T and B cell activation in models of autoimmune diseases, such as Crohn’s disease and lupus. The Clark lab aims to develop novel, first-in-class, drug therapies for cancer and autoimmune diseases. Figure 1: Biochemical pathways for the supply of deoxyribonucleoside triphosphate pools. The salvage pathway becomes upregulated during autoimmune diseases. FDA approved drugs blocking the de novo pathway include Aubagio (teriflunomide), Mavenclad (cladribine), and CellCept (mycophenolate mofetil). About TretheraTrethera is a clinical stage, privately held, biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members. Trethera's innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally administered capsule twice designated by the FDA as an Orphan Drug. TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors. It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth, and certain autoimmune diseases might also respond to TRE-515 treatment. Trethera is developing TRE-515 for use as a monotherapy or in combination to precisely target a metabolic vulnerability of cancer or autoimmune diseases that will transform outcomes for patients. For more information, please visit us at trethera.com or e-mail Investor Relations at ir@trethera.com. You can also follow Trethera on Facebook and LinkedIn. Note on Forward-Looking StatementsAll statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera believes or anticipates will or may occur in the future are “forward-looking statements,” which may often, but not always, be identified by the use of such words as "may," "might," "will," "will likely result," "would," "should," "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "continue," "target" or the negative of such terms or other similar expressions. Although Trethera has a reasonable basis for the forward-looking statements contained herein, Trethera cautions that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical and scientific research, all of which are difficult to predict and many of which are beyond Trethera’s control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation: the extent to which development of any novel cancer therapies or therapies for autoimmune diseases succeeds; whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research; Trethera successfully implementing its growth strategy, including that relating to its disease therapies; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; and risks and uncertainties applicable to the business of Trethera. The statements in this press release speak only as of the date hereof and Trethera does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a3669834-fb66-4439-930d-931d3a67f1b7

Reduced hospital stays with more patients discharged to home when treated with RNS60 Results presented during oral presentation at the American Academy of Neurology 2025 Annual Meeting TACOMA, Wash., April 9, 2025 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced new data from its completed Phase 2 RESCUE clinical trial of RNS60 in acute ischemic stroke patients, demonstrating that patients were discharged on average 4.8 days sooner (p=0.022) from the hospital following treatment with RNS60 plus standard of care endovascular thrombectomy (EVT) than patients who received an EVT alone. Patients who received RNS60 also experienced a reduction in infarct volume growth (brain tissue loss) post-EVT by more than 50% (p<0.05). These results were presented during an oral presentation at the American Academy of Neurology (AAN) 2025 Annual Meeting being held in San Diego, CA from April 5-9, 2025. "There is a lot of discussion currently taking place on improving human health while lowering the cost of healthcare. Given RNS60's Phase 2 results showing reduced brain tissue loss, improved function, and reductions in both hospital stay and the need for long-term care, RNS60 has the potential to greatly benefit patients and their families while lowering the economic burden of stroke," said Bert van den Bergh, Revalesio's Executive Chairman of the Board of Directors, and former President of Neuroscience Products at Eli Lilly and Company. "Revalesio's choice to capture infarct growth post-EVT is a great example of how Phase 2 clinical trials should be designed to properly evaluate cytoprotective drugs with the use of imaging to confirm results," said David S. Liebeskind, M.D., Director of the Neurovascular Imaging Research Core at UCLA. "I congratulate the investigators and Revalesio on their results and look forward to seeing RNS60 in a Phase 3 trial." Oral Presentation Highlights from the oral presentation to include: RNS60 high dose significantly lowered infarct growth by 50% (p<0.05) Subjects treated with RNS60 high dose were discharged 4.8 days sooner from the hospital (p=0.022) 55% of subjects treated with RNS60 high dose were discharged to their home compared to 21% of subjects treated with placebo 72% of subjects on RNS60 high dose were independent compared to 37% on placebo based on dichotomized modified Rankin Scale (0-2) at Day 90 RNS60 was safe and well tolerated "Our Phase 2 trial results sum up a decade's worth of research where the consistency in results has been remarkable. In preclinical models of stroke and traumatic brain injury, RNS60 reduced brain loss by up to 50%," said Greg Archambeau, President of Revalesio and co-inventor of RNS60. "Upon a potential FDA approval, we will be ready to rapidly scale our specialized U.S. manufacturing capability for RNS60 so patients won't have to wait." About the RESCUE Phase 2 Clinical Trial In RESCUE, a multi-center, double-blinded, placebo-controlled, randomized Phase 2 clinical trial, Revalesio evaluated the safety and initial efficacy of RNS60. Eighty-two participants with AIS eligible for endovascular thrombectomy (EVT) were enrolled and received intravenous RNS60 0.5 mL/kg/h (low dose), RNS60 1.0 mL/kg/h (high dose), or placebo starting before completion of the EVT and continuing for 48 hours. The trial had two primary endpoints: safety and mortality. Secondary endpoints for the study evaluated disability based on the well-established modified Rankin Scale (mRS), change in the size of the stroke as measured by MRI at 48 hours, and additional endpoints including Barthel Index, NIHSS, and EQ-5D-5L. About RNS60 RNS60 is an investigational therapeutic being developed to provide disease modifying and potentially restorative treatments for neurological diseases. In preclinical studies, RNS60 activated intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protected neurons and oligodendrocytes and modulated the activity of immune cells to restore homeostasis. About Revalesio Revalesio is a clinical-stage pharmaceutical company with a vision to change the future of treatment for acute and chronic neurological disorders. The company's lead clinical program for RNS60 is ischemic stroke with additional programs in ALS and other neurological disorders. The company's pioneering technology, founded in physics, addresses fundamental mechanisms involved with proper cellular function to slow disease progression and improve quality of life. For more information, please visit revalesio.com and engage with us on LinkedIn. Media: Lori Murray [email protected] SOURCE Revalesio Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Academic research teams of selected projects participate in a translational research program that eliminates barriers that prevent promising discoveries from getting to the clinicMENLO PARK, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- SPARK NS today announced the eight projects and principal investigators selected for the SPARK NS Translational Research Program, 2025 Cohort. Participation in a SPARK NS program cohort lasts two years and includes milestone-based funding of up to $2,000,0001 for each project, education and training in drug development and translational research for participating teams, mentoring from 75+ industry expert advisors, and scientific and business networking opportunities. SPARK NS is dedicated to advancing academic discoveries in Parkinson’s disease and autism around the world from the lab to the clinic. The eight projects selected for the 2025 Cohort focus on Parkinson’s disease. Combined with the five projects selected for the 2024 Cohort, SPARK NS now has 13 Parkinson’s disease projects based in the US and the UK actively participating in its translational research program and eligible for up to $26 million in aggregate funding. SPARK NS will release a Call for Proposals for the 2026 Cohort of the program in April 2025. For the 2026 Cohort, SPARK NS will accept applications from principal investigators in the US, Canada, UK, and Europe with projects focused on Parkinson’s disease and autism. “The typical drug development journey is long and expensive with many obstacles standing in the way of lab discoveries on the path to commercialization2,” said Daria Mochly-Rosen, PhD, a SPARK NS Board Director and Chief Science and Education Advisor. “Funding is essential, but it’s not enough. The SPARK NS program provides a high level of support at a crucial stage that prepares academic researchers for the rigor of the entire drug development process. Participating in the SPARK NS program improves the odds that promising therapeutics will make it to market where they can directly benefit patients.” Dr. Mochly-Rosen is the originator of the SPARK model of translational research, a unique approach to drug development refined over two decades that has achieved an exceptional success rate of 50%3 at advancing academic projects to licensing and/or clinical trials. The SPARK model is the foundation of the SPARK NS Translational Research Program. See the projects selected for the SPARK NS program 2025 and 2024 cohorts on our website here. Learn more about SPARK NS programs here. Projects and principal investigators selected for the 2025 Cohort are: Development of a Small-Molecule Therapy for Treating Parkinson’s Disease David S. Eisenberg, DPhil, Paul D. Boyer Chair of Biochemistry and Molecular Biology, University of California, Los AngelesBio: https://www.chemistry.ucla.edu/directory/eisenberg-david-s/ An Integrated Approach to Identifying Pharmacological Stabilizers for Parkinson’s Disease Mark Henderson, PhD, Group Leader, Biology, National Center for Advancing Translational Science (NCATS/NIH)Bio: https://ncats.nih.gov/about/our-staff/hendersonmj Targeting the Integrated Stress Response Pathway to Boost Mitophagy for Parkinson’s Disease Miratul Muqit, MBChB, PhD, Professor of Experimental Neurology, University of DundeeBio: https://www.dundee.ac.uk/people/miratul-muqit Restoring Mitochondrial Function in Parkinson’s Disease Michael P. Rapé, PhD, Professor of Molecular Therapeutics and Investigator, HHMI, University of California, BerkeleyBio: https://mcb.berkeley.edu/labs/rape/ A Bioenergetic Activator for Parkinson’s Disease Timothy A. Ryan, PhD, Professor of Biochemistry, Weill Cornell MedicineBio: https://sites.google.com/site/ryanlab1/Home Stimulating Endolysosomal Function for Parkinson’s Disease David K. Simon, MD, PhD, Professor of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical SchoolBio: https://research.bidmc.org/david-simon/people/dr-david-simon-0 A Disease Modifying Gene Therapy for Parkinson’s Disease for Multimodal Patient Benefit Kathy Steece-Collier, PhD, Professor, Department of Translational Neuroscience, Michigan State University College of Human MedicineBio: https://translationalscience.msu.edu/research-groups/steece-collier-lab.html Development of a Calcium Channel Inhibitor to Slow Parkinson’s Disease Progression D. James Surmeier, PhD, Nathan Smith Davis Professor and Chair, Department of Neuroscience, Feinberg School of Medicine, Northwestern UniversityBio: https://www.feinberg.northwestern.edu/faculty-profiles/az/profile.html?xid=13458 About SPARK NSSPARK NS is an independent nonprofit translational research organization founded in 2023 to advance promising academic discoveries in neuroscience from the lab to the clinic. SPARK NS focuses on Parkinson’s disease and autism. Through its ongoing translational research program, SPARK NS provides academic researchers with funding, extensive education in drug development, mentorship, and networking opportunities to close gaps in knowledge and know-how and eliminate barriers that slow or prevent promising discoveries from directly benefiting patients. As an independent nonprofit, SPARK NS is free to find and support the most promising projects and research teams in our areas of focus regardless of institutional affiliation. For more information, visit us at www.sparkns.org and follow us on LinkedIn. Contact:Susan Thomas Communications Director media@sparkns.org 1Not all funds awarded go directly to PIs’ laboratories. For example, work done by vetted research organizations or academic research facilities is paid for by SPARK NS directly to the organizations from awarded funds. 2Mochly-Rosen, D., and Grimes, K., Editors, Practical Guide to Drug Development in Academia: The SPARK Approach, Second Edition, Switzerland: Springer Nature (2023) 3Kim, J.S., Kargotich, S., Lee, S.H. et al. SPARKing academic technologies across the valley of death. Nature Biotechnology 42, 339-342 (2024).